Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Lorenzo Trippa, PhD


No Ratings Available - Why Not?

Researcher

  • Associate Professor, Harvard University
  • Co-Director, Program in Regulatory Science

Contact Information

  • Office Phone Number617-582-9133

Bio

Lorenzo Trippa, PhD, is an Associate Professor in the Department of Biostatistics and Computational Biology at Dana-Farber, and an Associate Professor in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. His research interests include clinical trials design; Bayesian nonparametrics; the development of prediction models in personalized medicine; computational methods for Bayesian adaptive designs; computational methods for Bayesian inference; and meta-analyses in personalized medicine. Trippa is a winner of the Savage PhD Thesis Award from the International Society for Bayesian Analysis. He holds a PhD in Statistics from Bocconi University, Milan, Italy, and an MS in Statistics (cum laude) from Milan’s Bicocca University.

Research

My research is focused on the following topics: Clinical Trials Design, Bayesian Nonparametrics, Development of Prediction Models in Personalized Medicine, Computational Methods for Bayesian Inference, Meta Analyses in Personalized Medicine

Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 Oct; 22(10):e456-e465.
View in: PubMed

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651.
View in: PubMed

Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 Sep 02.
View in: PubMed

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110.
View in: PubMed

Integration of survival data from multiple studies. Biometrics. 2021 Jun 30.
View in: PubMed

KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials. Database (Oxford). 2021 06 26; 2021.
View in: PubMed

The Use of External Control Data for Predictions and Futility Interim Analyses in Clinical Trials. Neuro Oncol. 2021 Jun 09.
View in: PubMed

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 Jul 20; 39(21):2375-2385.
View in: PubMed

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 Oct; 11(10):2474-2487.
View in: PubMed

Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304.
View in: PubMed

The effects of releasing early results from ongoing clinical trials. Nat Commun. 2021 02 05; 12(1):801.
View in: PubMed

Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol. Implement Sci. 2021 01 07; 16(1):9.
View in: PubMed

Reply to "Keynote 48: Is it really for everyone?" Oral Oncol. 2021 04; 115:105108.
View in: PubMed

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605.
View in: PubMed

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227.
View in: PubMed

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020 11; 31(11):1518-1525.
View in: PubMed

Shared and Usable Data From Phase 1 Oncology Trials-An Unmet Need. JAMA Oncol. 2020 07 01; 6(7):980-981.
View in: PubMed

Optimality of testing procedures for survival data in the nonproportional hazards setting. Biometrics. 2021 06; 77(2):587-598.
View in: PubMed

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in: PubMed

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020 09; 31(9):1231-1239.
View in: PubMed

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
View in: PubMed

Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724.
View in: PubMed

Keynote 48: Is it really for everyone? Oral Oncol. 2020 06; 105:104762.
View in: PubMed

A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly. Neuro Oncol. 2020 Apr 27.
View in: PubMed

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
View in: PubMed

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
View in: PubMed

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 06 15; 26(12):2838-2848.
View in: PubMed

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):238-245.
View in: PubMed

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
View in: PubMed

To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro Oncol. 2019 10 09; 21(10):1239-1249.
View in: PubMed

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
View in: PubMed

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123.
View in: PubMed

Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs. Clin Cancer Res. 2019 12 15; 25(24):7281-7286.
View in: PubMed

Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications. Clin Cancer Res. 2019 11 01; 25(21):6339-6345.
View in: PubMed

Frequentist operating characteristics of Bayesian optimal designs via simulation. Stat Med. 2019 09 20; 38(21):4026-4039.
View in: PubMed

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clin Cancer Res. 2019 08 15; 25(16):4993-5001.
View in: PubMed

Divining responder populations from survival data. Ann Oncol. 2019 06 01; 30(6):1005-1013.
View in: PubMed

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404.
View in: PubMed

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
View in: PubMed

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3.
View in: PubMed

Multi-study factor analysis. Biometrics. 2019 03; 75(1):337-346.
View in: PubMed

Bayesian adaptive design: the future for regional anesthesia trials? Reg Anesth Pain Med. 2019 Mar 02.
View in: PubMed

Bayesian Adaptive Randomization in Dose-Finding Trials. JAMA Netw Open. 2018 12 07; 1(8):e186075.
View in: PubMed

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
View in: PubMed

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018 07 05; 20(8):1034-1043.
View in: PubMed

Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol. 2018 09; 42(6):528-538.
View in: PubMed

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
View in: PubMed

Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. Biostatistics. 2018 04 01; 19(2):199-215.
View in: PubMed

Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy. N Engl J Med. 2018 03 22; 378(12):1158-1159.
View in: PubMed

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917.
View in: PubMed

Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. J Clin Oncol. 2017 Sep 20; 35(27):3160-3168.
View in: PubMed

Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res. 2017 Aug 15; 23(16):4680-4692.
View in: PubMed

Bayesian Nonparametric Ordination for the Analysis of Microbial Communities. J Am Stat Assoc. 2017; 112(520):1430-1442.
View in: PubMed

Bayesian response-adaptive designs for basket trials. Biometrics. 2017 09; 73(3):905-915.
View in: PubMed

Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017 04 27; 129(17):2429-2436.
View in: PubMed

Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials. J Clin Oncol. 2017 Feb 20; 35(6):681-687.
View in: PubMed

Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis. 2016 12 01; 20(12):8-12.
View in: PubMed

A Bayesian response-adaptive trial in tuberculosis: The endTB trial. Clin Trials. 2017 Feb; 14(1):17-28.
View in: PubMed

Robust lineage reconstruction from high-dimensional single-cell data. Nucleic Acids Res. 2016 08 19; 44(14):e122.
View in: PubMed

Mitigating Bias in Generalized Linear Mixed Models: The Case for Bayesian Nonparametrics. Stat Sci. 2016 Feb; 31(1):80-95.
View in: PubMed

Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers. Biometrics. 2016 06; 72(2):414-21.
View in: PubMed

On the restricted mean survival time curve in survival analysis. Biometrics. 2016 Mar; 72(1):215-21.
View in: PubMed

Unbiased estimation for response adaptive clinical trials. Stat Methods Med Res. 2017 Oct; 26(5):2376-2388.
View in: PubMed

Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. Neuro Oncol. 2015 May; 17(5):765-6.
View in: PubMed

Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
View in: PubMed

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13.
View in: PubMed

Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):E5643-50.
View in: PubMed

A toolbox for spatiotemporal analysis of voltage-sensitive dye imaging data in brain slices. PLoS One. 2014; 9(9):e108686.
View in: PubMed

Bayesian designs and the control of frequentist characteristics: a practical solution. Biometrics. 2015 Mar; 71(1):218-226.
View in: PubMed

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8.
View in: PubMed

Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials. Stat Biosci. 2016 Jun; 8(1):159-180.
View in: PubMed

Cross-study validation for the assessment of prediction algorithms. Bioinformatics. 2014 Jun 15; 30(12):i105-12.
View in: PubMed

Progression-free survival: too much risk, not enough reward? Neuro Oncol. 2014 May; 16(5):615-6.
View in: PubMed

Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 03; 106(5).
View in: PubMed

A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med. 2014 Jun 15; 33(13):2206-21.
View in: PubMed

Statistical tools and R software for cancer driver probabilities. Methods Mol Biol. 2014; 1101:113-34.
View in: PubMed

Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8.
View in: PubMed

Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1.
View in: PubMed

Defining Predictive Probability Functions for Species Sampling Models. Stat Sci. 2013; 28(2):209-222.
View in: PubMed

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63.
View in: PubMed

Bayesian enrichment strategies for randomized discontinuation trials. Biometrics. 2012 Mar; 68(1):203-11.
View in: PubMed

The multivariate beta process and an extension of the Polya tree model. Biometrika. 2011 Mar; 98(1):17-34.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
CLS 11017
Boston, MA 02215
Get Directions

Top